Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia
Abstract:Variations in the hepatitis C virus (HCV) core sequence have been related to
disease progression and response to antiviral therapy. Previously we showed
that the methylation status of RASSF1A and p16 genes, and IL28B genotypes
affects the response to pegylated interferon/ribavirin (PEG-IFN/RBV)
therapy. Herein we investigated whether amino acid (aa) substitutions in the
HCV core region alone or in combination with IL28B genotypes and RASSF1A/p16
methylation affect the response to PEG-IFN/RBV … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.